1. 1. Dalakas MC (2015) Inflammatory Muscle Diseases. New England Journal of Medicine, 372(18): 1734-47. [DOI:10.1056/NEJMra1402225]

2. Figarella‐Branger D, Civatte M, Bartoli C, Pellissier JF (2003) Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle & Nerve, 28(6): 659-82. [DOI:10.1002/mus.10462]

3. Mandel D, Malemud C, Askari A (2017) Idiopathic inflammatory myopathies: A review of the classification and impact of pathogenesis. Int J Molecular Sciences, 18(5): 1084. [DOI:10.3390/ijms18051084]

4. Dalakas MC (2011) Pathophysiology of inflammatory and autoimmune myopathies. La Presse Médicale, 40(4): e237-e47. [DOI:10.1016/j.lpm.2011.01.005]

5. Espinosa-Ortega F, Gómez-Martin D, Santana-De Anda K, Romo-Tena J, Villaseñor-Ovies P, Alcocer-Varela J (2015) Quantitative T-cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets. Clinical and Experimental Immunology, 179(3): 520-8. [DOI:10.1111/cei.12475]

6. Moran EM and Mastaglia FL (2014) The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscular Disorders, 24(11): 943-52. [DOI:10.1016/j.nmd.2014.06.432]

7. Miossec P and Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews Drug Discovery, 11(10): 763-76. [DOI:10.1038/nrd3794]

8. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YYJ, Beekman JM, van Beekum O, et al. (2010) Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood, 115(5): 965-74. [DOI:10.1182/blood-2009-02-207118]

9. Zhu S, Pan W, Qian Y (2013) MicroRNA in immunity and autoimmunity. Journal of Molecular Medicine, 91(9): 1039-50. [DOI:10.1007/s00109-013-1043-z]

10. Yan W, Chen C, Chen H (2016) Estrogen downregulates miR-21 expression and induces inflammatory infiltration of macrophages in polymyositis: Role of CXCL10. Molecular Neurobiology, 54(3): 1631-41. [DOI:10.1007/s12035-016-9769-6]

11. Allenbach Y, Solly S, Grégoire S, Dubourg O, Salomon B, Butler-Browne G, et al. (2009) Role of regulatory T Cells in a new mouse model of experimental autoimmune myositis. The American Journal of Pathology, 174(3): 989-98. [DOI:10.2353/ajpath.2009.080422]

12. Lennon VA, Lindstrom JM, Seybold ME (1975) Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. The Journal of Experimental Medicine, 141(6):1365-75. [DOI:10.1084/jem.141.6.1365]

13. Coughenour LL, McLean JR, Parker RB (1977) A new device for the rapid measurement of impaired motor function in mice. Pharmacology Biochemistry and Behavior, 6(3): 351-3. [DOI:10.1016/0091-3057(77)90036-3]

14. Kojima T, Tanuma N, Aikawa Y, Shin T, Sasaki A, Matsumoto Y (1997) Myosin-induced autoimmune polymyositis in the rat. Journal of the Neurological Sciences, 151(2): 141-8. [DOI:10.1016/S0022-510X(97)00148-2]

15. Fiedler SD, Carletti MZ, Christenson LK (2010) Quantitative RT-PCR methods for mature microRNA expression analysis. Methods Mol Biol, 630: 49-64. [DOI:10.1007/978-1-60761-629-0_4]

16. Liu C, Li B, Cheng Y, Lin J, Hao J, Zhang S, et al. (2011) MiR-21 plays an important role in radiation induced carcinogenesis in BALB/c mice by directly targeting the tumor suppressor gene Big-h3. Int J Biol Sci, 7(3): 347-63. [DOI:10.7150/ijbs.7.347]

17. Noack M and Miossec P (2014) Th17 and regulatory T-cell balance in autoimmune and inflammatory diseases. Autoimmunity Reviews, 13(6): 668-77. [DOI:10.1016/j.autrev.2013.12.004]

18. Shen H, Xia L, Lu J, Xiao W (2011) Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scandinavian Journal of Rheumatology, 40(3): 217-20. [DOI:10.3109/03009742.2010.517215]

19. Huo Yuping YH (2013) Detection and significance of peripheral blood regulatory T cells/helper T cells 17 in patients with dermatomyositis. Chinese Journal of Rheumatology, 17(2): 3.

20. Bartel DP (2004) MicroRNAs. Cell, 116(2): 281-97. [DOI:10.1016/S0092-8674(04)00045-5]

21. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, et al. (2008) Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. The Journal of Experimental Medicine, 205(9): 1983-91. [DOI:10.1084/jem.20080707]

22. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, et al. (2018) Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflammation and Regeneration, 38(1): 1. [DOI:10.1186/s41232-017-0058-1]

23. Parkes JE, Day PJ, Chinoy H, Lamb JA (2015) The role of microRNAs in the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 27(6): 608-15. [DOI:10.1097/BOR.0000000000000225]

24. Shimada S JM, Ogata A (2012) Serum miR-21 levels in patients with dermatomyositis. Clinical and Experimental Rheumatology, 31(1): 161.

25. Liston A, Linterman M, Lu L-F (2010) MicroRNA in the Adaptive Immune System, in Sickness and in Health. Journal of Clinical Immunology, 30(3): 339-46. [DOI:10.1007/s10875-010-9378-5]

26. Dai R and Ahmed SA (2011) MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Translational Research, 157(4): 163-79. [DOI:10.1016/j.trsl.2011.01.007]

27. Rouas R, Fayyad‐Kazan H, El Zein N, Lewalle P, Rothé F, Simion A, et al. (2009) Human natural Treg microRNA signature: Role of microRNA‐31 and microRNA‐21 in FOXP3 expression. European Journal of Immunology, 39(6): 1608-18. [DOI:10.1002/eji.200838509]

28. Murugaiyan G, da Cunha AP, Ajay AK, Joller N, Garo LP, Kumaradevan S, et al. (2015) MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. Journal of Clinical Investigation, 125(3): 1069-80. [DOI:10.1172/JCI74347]

29. Venugopal P, Koshy T, Lavu V, Ranga Rao S, Ramasamy S, Hariharan S, et al. 2018Differential expression of microRNAs let‐7a, miR‐125b, miR‐100, and miR‐21 and interaction with NF‐kB pathway genes in periodontitis pathogenesis. Journal of Cellular Physiology, 233(8): 5877-84. [DOI:10.1002/jcp.26391]

30. Rayavarapu S, Coley W, Kinder TB, Nagaraju K (2013) Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skeletal Muscle, 3(1): 13. [DOI:10.1186/2044-5040-3-13]

31. Ruan Q and Chen YH (2011) Nuclear factor-κB in immunity and inflammation: The treg and Th17 connection. Advances in Experimental Medicine and Biology: Springer New York, p. 207-21. [DOI:10.1007/978-1-4614-0106-3_12]

32. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL (2018) Classification and management of adult inflammatory myopathies. The Lancet Neurology, 17(9): 816-28. [DOI:10.1016/S1474-4422(18)30254-0]

33. Yang Z, Lin F, Qin B, Liang Y, Zhong R (2014) Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study. The Journal of Rheumatology, 42(2): 282-91. [DOI:10.3899/jrheum.140566]

34. Pauley KM, Cha S, Chan EKL (2009) MicroRNA in autoimmunity and autoimmune diseases. Journal of Autoimmunity, 32(3-4): 189-94. [DOI:10.1016/j.jaut.2009.02.012]

35. Chung KH (2006) Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Research, 34(7): e53-e. [DOI:10.1093/nar/gkl143]

36. Rupaimoole R and Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery, 16(3): 203-22. [DOI:10.1038/nrd.2016.246]